Recombinant Vaccine
Development
A New Era in Disease Prevention
At BioTechConsultancy, we are at the forefront of vaccine research, focusing on recombinant vaccines that provide powerful, safe, and targeted protection against infectious diseases. Our mission is to develop vaccines that are not only highly effective but also accessible to communities worldwide.
Understanding Recombinant Vaccines
Recombinant vaccines represent a major advancement in immunology. Unlike traditional vaccines, which often use weakened or inactivated pathogens, recombinant vaccines are created using genetic engineering. By isolating and reproducing specific proteins or antigens from a pathogen, these vaccines stimulate the immune system without exposing it to the entire organism.
This targeted approach reduces side effects while maximizing immune response, offering a safe and effective pathway to disease prevention.
From strategy to execution, our customized solutions
are designed to support innovation, efficiency, and
long-term success.
Types of Recombinant Vaccines
Our laboratory focuses on key areas of biomedical research, aiming to tackle some of the most critical health challenges of our time:
Live Attenuated / Killed
Uses weakened or inactivated microbes to stimulate strong immunity. Often effective with fewer doses, but formulation and safety controls are essential for consistent protection.
Subunit
Vaccines
Contains purified pathogen proteins or polysaccharides instead of whole organisms. Safer by design and highly targeted, usually paired with adjuvants to boost response.
Conjugate Vaccines
Links a weak antigen to a carrier protein to improve immune recognition. Especially useful for polysaccharide antigens and helps build stronger, longer-lasting immunity.
Synthetic Antigen Vaccines
Uses chemically synthesized antigen segments that mimic pathogen components. Enables precise design, scalable manufacturing, and consistent batches with strong quality control.
DNA / RNA Vaccines
Delivers genetic instructions so cells produce an antigen temporarily. Supports rapid development and flexible updates, while requiring optimized delivery and stability planning.
Viral Vector Vaccines
Uses a harmless viral carrier to deliver antigen genes into cells. Produces strong cellular and antibody responses, with careful vector selection and dose optimization.
Bacterial Vector Vaccines
Uses engineered bacteria to deliver antigen signals to the immune system. Can stimulate mucosal and systemic immunity, while requiring robust biosafety and containment controls.
VLP-Based Vaccines
Virus-like particles mimic viral structure without genetic material. Highly immunogenic and safe, commonly used when strong antibody responses are the main objective.
Cell-Based Vaccines
Uses modified cells to present antigens and stimulate immunity. Often explored in therapeutic settings and requires tight control of sourcing, processing, and potency testing.
Plant-Based Vaccines
Produces antigens in plants for scalable and cost-efficient production. Attractive for rapid scale-up, with emphasis on purification, consistency, and regulatory documentation.
Recombinant Bacterial Vaccines
Uses recombinant proteins produced in bacterial systems for vaccination. Cost-effective manufacturing with strong QC needs, including purity, endotoxin control, and stability testing.
Recombinant Viral Vaccines
Uses recombinant viral components to trigger protective immunity. Enables targeted antigen design and reliable production with attention to safety, stability, and immunogenicity.
Recombinant Fungal Targets
Focuses on recombinant antigens to address fungal infections. Designed to improve recognition and immune clearance, supporting safer development than whole-organism approaches.
Recombinant Parasite Targets
Uses selected parasite antigens to reduce infection and severity. Helps guide immune responses more precisely, with careful antigen selection for broad strain coverage.
HBV Recombinant Vaccines
Recombinant hepatitis B surface antigens generate strong protective antibodies. Widely validated approach with robust manufacturing controls for potency and consistency.
HPV Recombinant Vaccines
Uses recombinant HPV antigens, often as VLPs, to prevent infection. Supports long-term protection with strong antibody responses and well-established quality standards.
Therapeutic Metabolic
Explores immune strategies to improve metabolic control and inflammation pathways. Aims to support long-term disease management with clinically guided targets and monitoring.
Therapeutic Autoimmune
Designed to modulate immune tolerance and reduce harmful self-reactivity. Focuses on precision targets, safety monitoring, and evidence-based immunomodulation.
Neurodegenerative Targets
Investigates antigen strategies against disease-associated proteins. Aims to support early intervention research with strong safety frameworks and biomarker-driven evaluation.
Allergy Desensitization
Targets specific allergens to reduce sensitivity over time. Built around controlled exposure concepts, prioritizing safety, dose escalation planning, and clinical oversight.
Exosome-Based Platforms
Uses exosome systems to present or deliver immune-stimulating signals. A developing platform emphasizing reproducibility, characterization, and scalable manufacturing methods.
Universal Vaccine Concepts
Targets conserved regions shared across variants for broader protection. Focuses on durable immunity and reduced need for frequent updates through smart antigen design.
Tell us your goals-our team will recommend the
most suitable test and next steps.
Advancing Research from Bench to Bedside
At BiotechConsults, we are committed to turning innovation into action.
By combining scientific expertise, strategic insight, and collaborative networks, we help researchers move discoveries beyond the lab-into clinical practice, market-ready technologies, and solutions that enhance healthcare and quality of life.
Still have Qs?
What are recombinant vaccines, and how do they differ from traditional vaccines?
Are recombinant vaccines safe?
What types of diseases can recombinant vaccines target?
How quickly can recombinant vaccines be developed?
Can recombinant vaccines provide broad protection against
multiple strains?
